Incyte delivered exceptional core business growth and pipeline progress in Q4 2025, with total revenue increasing by 28% year-over-year to $1.51 billion and net product revenue rising by 20% to $1.22 billion, surpassing full-year guidance. The company also reported a significant increase in GAAP net income to $299.28 million and GAAP basic EPS to $1.52.

Incyte delivered robust revenue growth and significant improvement in operating income for Q3 2025, fueled by higher product demand across its portfolio, including Jakafi, Opzelura, and the newly launched Niktimvo.

Incyte delivered solid financial results in Q2 2025, driven by double-digit revenue growth and strong net income, supported by increased sales of Jakafi, Opzelura, and the new Niktimvo product.

Incyte delivered a robust quarter with $1.05B in total revenue, driven by strong performances from Jakafi and Opzelura. The company also benefited from the U.S. launch of Niktimvo and posted a solid net income of $158M.

Incyte reported strong fourth-quarter 2024 results, with total revenues increasing 16% year-over-year to $1.18 billion. Growth was primarily driven by Jakafi ($773M, +11% YoY) and Opzelura ($162M, +48% YoY). GAAP net income remained stable at $201M, while non-GAAP net income rose 18% to $281M. GAAP diluted EPS was $1.02, and non-GAAP diluted EPS was $1.43.

Incyte reported a 24% increase in total revenues to $1,138 million in Q3 2024. Key drivers were Jakafi and Opzelura, with Jakafi's net product revenues increasing by 16% and Opzelura's by 52%. The company is raising its full year 2024 Jakafi revenue guidance to $2,740 - $2,770 million. The FDA approved Niktimvo for chronic graft-versus-host disease.

Incyte reported total revenues of $1,044 million for Q2 2024, a 9% increase year-over-year. The company completed a $2.0 billion share repurchase and is focusing R&D on high-impact clinical programs.

Incyte reported total revenues of $881 million for Q1 2024, a 9% increase year-over-year. The growth was primarily driven by patient demand for Opzelura and Jakafi in the U.S., although offset by a Jakafi inventory drawdown. Incyte is acquiring Escient Pharmaceuticals to expand its pipeline.

Incyte reported a strong Q4 2023, marked by total revenues of $1.013 billion. The company's performance was driven by the continued growth of Jakafi and the successful launch of Opzelura. Incyte is focused on advancing its high potential pipeline, with plans for over 10 new launches by 2030.

Incyte reported a 12% year-over-year increase in total revenues, reaching $919 million in Q3 2023. This growth was primarily driven by the sustained performance of Jakafi and the increasing contribution from Opzelura. The company also made significant progress in its early programs in myeloproliferative neoplasms (MPNs) and received positive top line results from the Phase 2 study of povorcitinib in prurigo nodularis (PN).

Incyte's Q2 2023 financial results showed strong growth, with total net product revenues increasing by 25% year-over-year to $827 million. This growth was primarily driven by Jakafi and Opzelura. The company is advancing its pipeline with positive results for ruxolitinib cream in pediatric atopic dermatitis and axatilimab in chronic graft-versus-host disease.

Incyte reported strong Q1 2023 results, with total net product revenues of $693 million, a 14% increase year-over-year. Jakafi revenues grew across all indications, and Opzelura is on track to become one of the most successful dermatology launches in recent years. The company also expanded its commercial portfolio with several regulatory approvals.

Incyte reported Q4 2022 total GAAP revenues of $926.7 million, a 7% increase compared to Q4 2021. Jakafi net revenues were $647.5 million, a 9% increase year-over-year. Opzelura net revenues reached $61.3 million, driven by strong demand in atopic dermatitis and vitiligo.

Incyte reported a 20% year-over-year increase in total net product revenues, driven by strong performance from Jakafi and Opzelura. The company is progressing its pipeline across Oncology and Dermatology, with multiple updates on key programs expected in the coming months. Incyte also updated its full year 2022 guidance for Jakafi net product revenues and other Hematology/Oncology net product revenues.

Incyte reported strong second-quarter results with total revenues increasing by 29% year-over-year to $911 million. The company highlighted multiple approvals and continued advancement of its pipeline, including the launch of Opzelura in atopic dermatitis and its approval for nonsegmental vitiligo.

Incyte reported a strong first quarter with a 20% increase in total product and royalty revenues, reaching $728 million. Jakafi's net product revenues grew by 17% to $544 million, and Opzelura saw a robust uptake with over 38,000 new patients treated. The company is progressing with its clinical development programs, including regulatory submissions for ruxolitinib cream and advancements in its MPN and GVHD portfolios.

Incyte reported a 20% increase in total product and royalty revenues to $813 million for Q4 2021, driven by robust demand for Jakafi, continued uptake of Pemazyre, and a rapidly growing royalty revenue stream. The company also saw a successful U.S. launch of Opzelura with nearly 19,000 patients treated since launch.

Incyte reported a strong third quarter performance with total product and royalty revenues of $778 million, a 25% increase compared to Q3 2020. The company's growth was driven by double-digit growth in patient demand for Jakafi, continued uptake of Pemazyre and Minjuvi, and a significant increase in royalty revenue.

Incyte reported a strong second quarter with total product and royalty revenues reaching $696 million, a 17% increase compared to Q2 2020. Jakafi revenues grew by 12%, and there was encouraging uptake in Europe for Pemazyre. The company also saw clinical development success across its portfolio, including positive outcomes from ruxolitinib cream's pivotal trials in vitiligo and 52-week safety and efficacy data in atopic dermatitis.

Incyte reported its Q1 2021 financial results, highlighting a 6% increase in product and royalty revenues compared to the previous year, driven by Jakafi net product revenues, Pemazyre launch, and higher product royalty revenues from Jakavi and Olumiant. The company is progressing with multiple regulatory filings and pivotal trials across key development programs.

Incyte reported its 2020 fourth quarter and year-end financial results, highlighting strong revenue growth driven by Jakafi and the launches of Monjuvi and Pemazyre. The company also provided 2021 financial guidance and updates on key clinical programs, anticipating regulatory decisions on seven applications and a potential U.S. launch of ruxolitinib cream.

Incyte reported strong Q3 2020 financial results, driven by Jakafi sales, successful launches of Monjuvi and Pemazyre, and increasing royalty revenues. The company is also advancing its dermatology franchise and key clinical programs.

Incyte's Q2 2020 financial results showed a 16% increase in product and royalty revenues compared to the prior year, driven by growth in Jakafi net product revenues and higher product royalty revenues from Jakavi and Olumiant. The company reaffirmed its full-year 2020 financial guidance and highlighted key clinical program updates, including positive data for parsaclisib in combination with ruxolitinib in myelofibrosis patients and the FDA approval of Monjuvi for relapsed or refractory DLBCL.

Incyte's first quarter results demonstrated continued revenue growth, particularly driven by Jakafi. The company also achieved FDA approval for Pemazyre and is progressing with other potential product approvals. Despite the COVID-19 pandemic, Incyte has maintained its commercial operations and clinical trials.

Incyte reported its Q4 and year-end financial results for 2019, highlighting strong revenue growth driven by Jakafi. The company also announced 2020 financial guidance and provided updates on its key clinical programs.